Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Current Treatment of Myoclonic Astatic Epilepsy: Clinical Experience at the Children's Hospital of Philadelphia
Epilepsia, 10/05/07
Kilaru, S., et al. - Myoclonic astatic epilepsy (MAE) is a generalized epilepsy of early childhood. Little is known about the use of newer antiepileptic treatments (AET) in MAE. The purpose of this study was to describe the characteristics, treatment, and outcome of a contemporary MAE cohort exposed to the new generation AET...Conclusions: The new generation of AET may offer significant benefit to children with MAE. The KD was the most effective AET in this series, and perhaps should be considered earlier in treatment
Related Articles
Early Myoclonic Encephalopathy and Nonketotic Hyperglycinemia
Pediatric Neurology, 10/20/09
Relevance Score: 87%
The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus
Epilepsia, 11/05/09
Relevance Score: 82%
Current and future treatment of epilepsy
The Internet Journal of Neurology, 11/03/09
Relevance Score: 82%
Epilepsy in later life
The Lancet Neurology, 10/19/09
Relevance Score: 82%
Visual Field Loss in Patients with Refractory Partial Epilepsy Treated with Vigabatrin: Final Results from an Open-Label, Observational, Multicentre Study
CNS Drugs, 10/28/09
Relevance Score: 81%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial
European Journal of Neurology, 11/21/09
Metabolic Alterations During Valproic Acid Treatment: A Prospective Study
Pediatric Neurology , 11/21/09
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Neurology, 11/20/09
Sponsor
Article Search
Sponsor


See Latest Articles


